H1-Histamine Receptor Affinity Predicts Short-Term Weight Gain for Typical and Atypical Antipsychotic Drugs
By W. Kroeze, S. Hufeisen, Beth A Popadak, Sean M Renock, SeAnna Steinberg, P. Ernsberger, K. Jayathilake, H. Meltzer, Bryan L. Roth. Neuropsychopharmacology, 2003
767 citations recorded by the source corpus.
Subfields: Cellular and Molecular Neuroscience, Endocrine and Autonomic Systems, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/fff03cc6344e0095dd988ee27be7dec31f2bad8e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cellular and Molecular Neuroscience
In Endocrine and Autonomic Systems
In Molecular Biology
Citations in the corpus
- Tricyclic antidepressant pharmacology and therapeutic drug interactions updated (2007, background): “There are insufficient data on muscarinic receptor subtypes (m1–6) to compare drugs (PDSP data).”
- The Expanded Biology of Serotonin (2009, unknown): “These findings may help explain the diverse side effects of serotonergic drugs— from diabetes and metabolic syndrome to valvular heart disease (6, 7).”
- Aripiprazole, A Novel Atypical Antipsychotic Drug with a Unique and Robust Pharmacology (2003, background): “…from the serotonin (5-HT1A, 5-HT2C, 5-HT6, 5-HT7) (Roth et al, 1992, 1994, 1998), dopamine (D3, D4) (Roth et al, 1995; Sokoloff et al, 1990; Van Tol et al, 1991), muscarinic cholinergic (Stanton et al, 1993; Zeng et al, 1997), and histamine families (Kroeze et al, 2003; Roth et al, in press).”